Evidence map›Paper›PMID 24380829›Full record

ArticleEuropean journal of pharmacology2014

Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro.

Nidhi Kaushal, Matthew J Robson, Abagail Rosen, Christopher R McCurdy, Rae R Matsumoto

Open access · greenAbstract read
In one paragraph

Article in European journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nidhi KaushalDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA.
Matthew J RobsonDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA.
Abagail RosenDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA.
Christopher R McCurdyDepartment of Medicinal Chemistry, School of Pharmacy, University of Mississippi, MS 38677, USA.
Rae R MatsumotoDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA. Electronic address: rmatsumoto@hsc.wvu.edu.
West Virginia University · USUniversity of Mississippi · US

Funding

Synthesis &Evaluation of Cocaine AntagonistsR01DA013978 · NIDA · WEST VIRGINIA UNIVERSITY · PI MATSUMOTO, RAE R · 2001 to 2010
$1.9M
Novel Pharmacologic Interventions for Drugs of AbuseR01DA023205 · NIDA · UNIVERSITY OF MISSISSIPPI · PI MCCURDY, CHRISTOPHER R · 2007 to 2011
$1.7M
NIDA NIH HHS DA013978NIDA NIH HHS DA023205NIDA NIH HHS R01 DA013978NIDA NIH HHS R01 DA023205
6 · The paper itself

Abstract

Exposure to high or repeated doses of methamphetamine can cause hyperthermia and neurotoxicity, which are thought to increase the risk of developing a variety of neurological conditions. Sigma receptor antagonism can prevent methamphetamine-induced hyperthermia and neurotoxicity, but the underlying cellular targets through which the neuroprotection is conveyed remain unknown. Differentiated NG108-15 cells were thus used as a model system to begin elucidating the neuroprotective mechanisms targeted by sigma receptor antagonists to mitigate the effects of methamphetamine. In differentiated NG108-15 cells, methamphetamine caused the generation of reactive oxygen/nitrogen species, an increase in PERK-mediated endoplasmic reticulum stress and the activation of caspase-3, -8 and -9, ultimately resulting in apoptosis at micromolar concentrations, and necrotic cell death at higher concentrations. The sigma receptor antagonist, 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), attenuated methamphetamine-induced increases in reactive oxygen/nitrogen species, activation of caspase-3, -8 and -9 and accompanying cellular toxicity. In contrast, 1,3-di(2-tolyl)-guanidine (DTG), a sigma receptor agonist, shifted the dose response curve of methamphetamine-induced cell death towards the left. To probe the effect of temperature on neurotoxicity, NG108-15 cells maintained at an elevated temperature (40 °C) exhibited a significant and synergistic increase in cell death in response to methamphetamine, compared to cells maintained at a normal cell culture temperature (37 °C). SN79 attenuated the enhanced cell death observed in the methamphetamine-treated cells at 40 °C. Together, the data demonstrate that SN79 reduces methamphetamine-induced reactive oxygen/nitrogen species generation and caspase activation, thereby conveying neuroprotective effects against methamphetamine under regular and elevated temperature conditions.

Indexed as

AnimalsApoptosisBenzoxazolesCaspasesCell Line, TumoreIF-2 KinaseFeverLigandsMethamphetamineMiceNecrosisNeuroprotective AgentsPiperazinesReactive Nitrogen SpeciesReactive Oxygen SpeciesReceptors, sigma6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo(d)oxazol-2(3H)-oneBenzoxazolesCaspaseseIF-2 KinaseLigandsMethamphetamineNeuroprotective AgentsPiperazinesReactive Nitrogen SpeciesReactive Oxygen SpeciesReceptors, sigmaApoptosisCaspaseMethamphetamineNecrosisReactive oxygen speciesSigma receptors

Identifiers

PMID24380829
PMCPMC3993961
OpenAlexW2149616186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.